Histomorphometric analysis of glucocorticoid-induced osteoporosis.
Bone histomorphometry or quantitative histology consists of counting or measuring tissue components: cells, extracellular constituents and microarchitecture. Bone histomorphometry is the only method that allows the measurement of mineralization rate and the study of bone formation at three levels: cell, remodeling unit and tissue levels. It is a useful tool to explain the pathogenesis and cellular mechanisms of different metabolic bone diseases such as glucocorticoid-induced osteoporosis (GIO). Glucocorticoids (GC) affect calcium and bone metabolism at every level, but the main effect is the osteoblastic dysfunction. Concerning the bone formation, some histomorphometric studies have shown a depressed osteoblastic activity at a cell, bone remodeling unit, and tissue levels. In addition, there is evidence of a shortening of the period in which the osteoblasts work actively forming the bone matrix. This latter effect seems to occur after high cumulative doses of GC. With regard to the resorption, the results are still debated, but histomorphometric parameters seem to be increased in the majority of studies, at least in the first period of the GC treatment. From a structural point of view, GC seem to induce a thinning of the trabeculae without their perforation, which occurs only after high cumulative doses. Anti-resorptive treatments, such as bisphosphonates, are able to counteract the negative effects of GC on bone. In particular, along with their active working period, they prolong the lifespan of osteoblasts and osteocytes. In addition, the anti-resorptive treatments seem to extend the time for secondary mineralization through a reduction of the Activation Frequency. The latter is an intriguing mechanism of bisphosphonates in GIO that needs further ad hoc investigations.
Dalle Carbonare
L
L
Department of Biomedical and Surgical Sciences, Medicina Interna D, University of Verona, Italy. luca.dallecarbonare@univr.it
Bertoldo
F
F
Valenti
M T
MT
Zenari
S
S
Zanatta
M
M
Sella
S
S
Giannini
S
S
Cascio
V Lo
VL
D000818:Animals; D001857:Bone Matrix / Q000473:pathology / Q000503:physiopathology / Q000648:ultrastructure; D016723:Bone Remodeling / Q000502:physiology; D001862:Bone Resorption / Q000503:physiopathology; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D002113:Calcification, Physiologic / Q000502:physiology; D004164:Diphosphonates / Q000494:pharmacology; D005938:Glucocorticoids / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D010006:Osteoblasts / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology; D010024:Osteoporosis / Q000139:chemically induced* / Q000473:pathology* / Q000503:physiopathology; D015663:Osteoporosis, Postmenopausal / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology
D004164:Diphosphonates; D005938:Glucocorticoids